Tech Company Inital Public Offerings

BioAtla IPO

BioAtla, operating out of San Diego, debuted as a public company on 12/15/2020.

Transaction Overview

Company Name
Announced On
Transaction Type
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows:approximately $40.0 million to $60.0 million to fund the clinical development of BA3011 for the treatment of soft tissue and bone sarcoma patients through a Phase 2 clinical trial and for the treatment of NSCLC patients through a Phase 2 clinical trial;approximately $40.0 million to $60.0 million to fund the clinical development of BA3021 for the treatment of NSCLC and for the treatment of melanoma, each through a Phase 2 clinical trial;approximately $20.0 million to $30.0 million to fund IND-enabling studies and initial Phase 1 clinical supply of our first two CAB bispecific candidates;approximately $5.0 million to $10.0 million to fund our ongoing efforts to develop additional clinical product candidates from our CAB platform; andthe remaining proceeds for working capital and other general corporate purposes.

Company Information

Company Status
Mailing Address
11085 Torreyana Rd.
San Diego, CA 92121
Email Address
BioAtla (Nasdaq: BCAB) is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO) platforms.
BioAtla LinkedIn Company Profile
Social Media
BioAtla Company Twitter Account
Company News
BioAtla News
BioAtla on Facebook
BioAtla on YouTube

Management Team

Email & Social
Chief Executive Officer
Jay Short
  Jay Short LinkedIn Profile  Jay Short Twitter Account  Jay Short News  Jay Short on Facebook
Chief Financial Officer
Richard Waldron
  Richard Waldron LinkedIn Profile  Richard Waldron Twitter Account  Richard Waldron News  Richard Waldron on Facebook
Chief Scientific Officer
Gerhard Frey
  Gerhard  Frey LinkedIn Profile  Gerhard  Frey Twitter Account  Gerhard  Frey News  Gerhard  Frey on Facebook
Carolyn Short
  Carolyn Short LinkedIn Profile  Carolyn Short Twitter Account  Carolyn Short News  Carolyn Short on Facebook
Vice President
William Boyle
  William Boyle LinkedIn Profile  William Boyle Twitter Account  William Boyle News  William Boyle on Facebook
Vice President
Philippe Martin
  Philippe Martin LinkedIn Profile  Philippe Martin Twitter Account  Philippe Martin News  Philippe Martin on Facebook
Vice President
Monica Sullivan
  Monica Sullivan LinkedIn Profile  Monica Sullivan Twitter Account  Monica Sullivan News  Monica Sullivan on Facebook
VP - Bus. Development
Michael Melnick
  Michael Melnick LinkedIn Profile  Michael Melnick Twitter Account  Michael Melnick News  Michael Melnick on Facebook
VP - Human Resources
Susie Melody
  Susie Melody LinkedIn Profile  Susie Melody Twitter Account  Susie Melody News  Susie Melody on Facebook
VP - R & D
Cathy Chang
  Cathy Chang LinkedIn Profile  Cathy Chang Twitter Account  Cathy Chang News  Cathy Chang on Facebook



Browse more venture capital transactions:

Prev: 12/15/2020: venture capital transaction
Next: 12/15/2020: GoFor Industries venture capital transaction


Share this article


News on VC Transactions

Our team works diligently to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary